narsoplimab · Yartemlea
Monoclonal antibody
Also known as OMS721
Evidence outlook
Approved: Thrombotic Microangiopathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
aHUS NCT03205995 · Thrombotic Microangiopathy Registry: NCT03205995 | 3 | Platelet Count (10^9 Platelets/L) Change From Baseline at Week 26 2021-02-02 | Platelet Count (10^9 Platelets/L) Change From Baseline at Week 26 (Week 26): OMS721 (Narsoplimab) 42 10^9 platelets/L (range -21 to 115.5) | not yet graded | link ↗ |
View 1 more trial
NCT02222545 NCT02222545 · Thrombotic Microangiopathy Registry: NCT02222545 | 2 | Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA (Day 1 to 37 days after end of treatment, approximately up to 31 weeks.); Number of Participants With HSCT-TMA Who Respond to OMS721 (Day 1 to up to 2 years following the first dose of OMS721) 2020-01-30 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Thrombotic Microangiopathy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Narsoplimab (Yartemlea): this drug | Approved | Monoclonal antibody | MASP-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Eculizumab (Soliris) | Approved | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Yartemlea (narsoplimab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
July 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent